Morgan Giannattasio
Director of Clinical Partnerships
Verici Dx
Drew Silverman
Director of Scientific Communications
Verici Dx
Tutivia ™
A precise multi-gene RNA signature developed through AI techniques to provide an early warning blood-based assay that can detect all types of acute rejection, preceding traditional markers. Clinicians can use this test for both high risk or low risk individuals from the first week post-transplant and during follow-ups, regardless of delayed graft function, multiple transplants, or BK nephropathy.
VericiDx is excited to announce that our Tutivia validation study is available as open access in the March American Journal of Transplantation.
To access the Tutivia validation study click here.
Actionable Risk Scores for Every Patient
Coffee & Cases is a series where medical experts discuss real-world cases over a cup of coffee. In Episode 1, Dr. Zahraa Hajjiri, the Medical Director of the Transplant Program at the University of Illinois at Chicago, explores Delayed Graft Function, a crucial topic in transplant medicine. This episode provides valuable insights into its causes, challenges, and management strategies.
Personalized Testing for Individualizing Care
Verici Dx kidney transplant tests utilize next-generation sequencing to create a personalized and precise risk profile for each patient throughout their transplant journey. From a simple blood draw, our tests not only assess individual risk but may also detect potential acute rejection before traditional clinical and pathological methods can.
